Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed multiple myeloma
Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed multiple myeloma
Optimising immunoglobulin dosing can enhance patient outcomes in multiple myeloma
Oncologists' perspectives and practices on minimal residual disease testing in multiple myeloma
The need for improved healthcare infrastructure for extranodal NK/T-cell lymphoma in Latin America
Insights into germline genetic screening of breast cancer patients
Daratumumab and lenalidomide for frail patients with newly diagnosed multiple myeloma shows promising survival results
High-fibre dietary intervention in precursor plasma cell disorders improves biomarkers of disease, may delay progression to myeloma
Lack of benefit of auto-HCT in MCL patients in first complete remission with undetectable MRD
SABCS 2024: Highlights in breast cancer genomic testing
KRdc as induction therapy shows improved OS for NDMM patients
Epcoritamab monotherapy is well tolerated and efficacious in patients with r/r CLL
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer